You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Express Scripts
McKinsey
Johnson and Johnson
Merck

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

Patent: 9,211,341

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,211,341
Title:Method of manufacturing a pharmaceutical composition having chelating type complex micelles
Abstract: This invention provides Chelating Complex Micelles as a drug carrier. The Chelating Complex Micelles can load drugs without changing their structure, and therefore extend the half-life of drugs in the human body. The chelating complex micelles contain a metal ion core, at least one polymer, and at least one drug molecule. The metal ion is considered as a Lewis acid while polymer chain and drug molecules are referred to as Lewis bases. The drug molecule is linked to the polymer via forming coordinate bonds with metal ion, and then self-assembled to form chelating complex micelles as a drug carrier.
Inventor(s): Wang; Chau-Hui (Kaohsiung, TW), Chen; Chia-Hung (New Taipei, TW), Lin; Johnson (Taipei, TW), Chen; Jing-Yi (Taipei, TW), Liao; Wei-Chuan (Kaohsiung, TW)
Assignee: ORIGINAL BIOMEDICALS CO., LTD. (Tainan City, TW)
Application Number:14/306,775
Patent Claims:see list of patent claims

Details for Patent 9,211,341

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial ORIGINAL BIOMEDICALS CO., LTD. (Tainan City, TW) 2032-11-21 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial ORIGINAL BIOMEDICALS CO., LTD. (Tainan City, TW) 2032-11-21 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial ORIGINAL BIOMEDICALS CO., LTD. (Tainan City, TW) 2032-11-21 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial ORIGINAL BIOMEDICALS CO., LTD. (Tainan City, TW) 2032-11-21 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial ORIGINAL BIOMEDICALS CO., LTD. (Tainan City, TW) 2032-11-21 RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial ORIGINAL BIOMEDICALS CO., LTD. (Tainan City, TW) 2032-11-21 RX Orphan search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial ORIGINAL BIOMEDICALS CO., LTD. (Tainan City, TW) 2032-11-21 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,211,341

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Boehringer Ingelheim
Baxter
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.